The Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, estimated at USD 1,610.0 Mn in 2025, is expected to exhibit a CAGR of 4.3% and reach USD 2,161.8 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adoption of growth strategies such as launch of new products, or FDA clearance, and this is expected to drive the global relapsed or refractory diffuse large B cell lymphoma market growth. For instance, in December 2021, Cellular Biomedicine Group Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) had granted clearance to Investigational New Drug (IND) application to proceed with the Phase 1b clinical development of its chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (C-CAR039). C-CAR039 is a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens in the treatment of patients with relapsed or refractory non-Hodgkin lymphoma (r/r B-cell NHL).
Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding the transportation of things from one place to another.
COVID-19 had negative impact on the global relapsed or refractory diffuse large B cell lymphoma market. Patients with advanced cancer were not monitored or treated at home because there were no beds available for R/R DLBCL patients.
Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Key Developments
On September 25, 2023, Genmab A/S, an international biotechnology company, announced that the European Commission (EC) had granted conditional marketing authorization for TEPKINLY (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as Liechtenstein, Norway and Iceland.
Browse 26 Market Data Tables and 29 Figures spread through 145 Pages and in-depth TOC on “Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market”- Forecast to 2030, Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market:
- Global relapsed or refractory diffuse large B cell lymphoma market is expected to exhibit a CAGR of 4.3% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global relapsed or refractory diffuse large B cell lymphoma market.
- Among drug type, the monjuvi segment is expected to hold a dominant position in the global relapsed or refractory diffuse large B cell lymphoma market during the forecast period, owing to product success in the clinical trials in the field of relapsed or refractory diffuse large B cell lymphoma. For instance, in July 2020, MorphoSys AG, a commercial-stage biopharmaceutical company, and Incyte, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). Monjuvi, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, had been approved under accelerated approval by the U.S. FDA based on overall response rate (ORR). Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
- Among region, North America is expected to be the dominant region in the global relapsed or refractory diffuse large B cell lymphoma market, owing to the key players are focusing on organic strategies to start new product launches. For instance, on May 19, 2023, AbbVie Inc., a U.S.-basedpharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), after two or more lines of systemic therapies. EPKINLY is approved under the U.S. FDA's accelerated approval program based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. EPKINLY is being co-developed by AbbVie and Genmab, a Danish biotechnology company, as part of the companies' oncology
- Major players operating in the global relapsed or refractory diffuse large B cell lymphoma market are MorphoSys U.S. Inc., Bristol-Myers Squibb Company, Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.
Contact Us